Research programme: coagulation factor modulators - Aronora

Drug Profile

Research programme: coagulation factor modulators - Aronora

Alternative Names: AB-002; AB-012; AXIMAB; EWE-thrombin; ProCase; WE-thrombin

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oregon Health & Science University; Washington University
  • Developer Aronora; Oregon Health & Science University; Washington University
  • Class Enzymes; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Factor IX inhibitors; Factor XI inhibitors; Factor XIIa inhibitors; Thrombin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cardiovascular disorders; Sepsis; Venous thrombosis

Most Recent Events

  • 09 Mar 2018 Preclinical development is ongoing in USA
  • 09 Mar 2018 Aronora plans a phase I trial for thrombosis in USA in June 2018 (NCT03453060)
  • 05 Apr 2017 Aronora plans a phase I trial of Xisomab for Thrombosis (In volunteers) (NCT03097341)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top